Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Identifieur interne : 002737 ( PubMed/Curation ); précédent : 002736; suivant : 002738Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Auteurs : Shixia Wang [États-Unis] ; Pavlo Sakhatskyy ; Te-Hui W. Chou ; Shan LuSource :
- Journal of immunological methods [ 0022-1759 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Anticorps antiviraux.
- immunologie : Anticorps antiviraux, Syndrome respiratoire aigu sévère, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Reproductibilité des résultats, Tests de neutralisation.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Antibodies, Viral.
- chemical , immunology : Antibodies, Viral.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Neutralization Tests, Reproducibility of Results, Vero Cells.
Abstract
Accurate assessment of neutralizing antibody activities is important either for patients infected with Severe Acute Respiratory Syndrome (SARS) or for animals and volunteers immunized with the experimental vaccines against the SARS associated coronavirus (SCV). However, the current assay based on the cytopathic effect (CPE) which has been frequently cited in literature has several limitations. The CPE assay relies on the visual observation on the damage of SCV infected target cells under a microscope. It is subjected to observer variations and it is difficult to generate a quantitative determination of neutralizing activities based on the level of CPE. In the current study, we established the utility of two additional assays to measure the neutralizing activities against SCV: the plaque reduction (PR) and the neutral red staining (NRS) assays. The PR assay described in this study was modified from the traditional viral plaque reduction assay by using an improved crystal staining method to achieve better plague formation in SCV infected Vero E6 cells. The NRS neutralization assay was adopted from a similar system used for detecting neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1). In this assay, the protective effect of neutralizing antibodies was determined by the cell viability which is measured by the uptake of neutral red dye at A540. The neutralizing antibody titers can be easily determined with either of the two new assays. In this report, we described the utility of these two new neutralization assays in measuring the neutralizing activities against SCV infection from rabbit sera immunized with various forms of spike protein of SCV.
DOI: 10.1016/j.jim.2005.03.008
PubMed: 15894326
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002737
Links to Exploration step
pubmed:15894326Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).</title><author><name sortKey="Wang, Shixia" sort="Wang, Shixia" uniqKey="Wang S" first="Shixia" last="Wang">Shixia Wang</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397</wicri:regionArea></affiliation></author><author><name sortKey="Sakhatskyy, Pavlo" sort="Sakhatskyy, Pavlo" uniqKey="Sakhatskyy P" first="Pavlo" last="Sakhatskyy">Pavlo Sakhatskyy</name></author><author><name sortKey="Chou, Te Hui W" sort="Chou, Te Hui W" uniqKey="Chou T" first="Te-Hui W" last="Chou">Te-Hui W. Chou</name></author><author><name sortKey="Lu, Shan" sort="Lu, Shan" uniqKey="Lu S" first="Shan" last="Lu">Shan Lu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15894326</idno><idno type="pmid">15894326</idno><idno type="doi">10.1016/j.jim.2005.03.008</idno><idno type="wicri:Area/PubMed/Corpus">002737</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002737</idno><idno type="wicri:Area/PubMed/Curation">002737</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002737</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).</title><author><name sortKey="Wang, Shixia" sort="Wang, Shixia" uniqKey="Wang S" first="Shixia" last="Wang">Shixia Wang</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397</wicri:regionArea></affiliation></author><author><name sortKey="Sakhatskyy, Pavlo" sort="Sakhatskyy, Pavlo" uniqKey="Sakhatskyy P" first="Pavlo" last="Sakhatskyy">Pavlo Sakhatskyy</name></author><author><name sortKey="Chou, Te Hui W" sort="Chou, Te Hui W" uniqKey="Chou T" first="Te-Hui W" last="Chou">Te-Hui W. Chou</name></author><author><name sortKey="Lu, Shan" sort="Lu, Shan" uniqKey="Lu S" first="Shan" last="Lu">Shan Lu</name></author></analytic><series><title level="j">Journal of immunological methods</title><idno type="ISSN">0022-1759</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (analysis)</term><term>Antibodies, Viral (immunology)</term><term>Chlorocebus aethiops</term><term>Neutralization Tests</term><term>Reproducibility of Results</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vero Cells</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (analyse)</term><term>Anticorps antiviraux (immunologie)</term><term>Cellules Vero</term><term>Reproductibilité des résultats</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Neutralization Tests</term><term>Reproducibility of Results</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Reproductibilité des résultats</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Accurate assessment of neutralizing antibody activities is important either for patients infected with Severe Acute Respiratory Syndrome (SARS) or for animals and volunteers immunized with the experimental vaccines against the SARS associated coronavirus (SCV). However, the current assay based on the cytopathic effect (CPE) which has been frequently cited in literature has several limitations. The CPE assay relies on the visual observation on the damage of SCV infected target cells under a microscope. It is subjected to observer variations and it is difficult to generate a quantitative determination of neutralizing activities based on the level of CPE. In the current study, we established the utility of two additional assays to measure the neutralizing activities against SCV: the plaque reduction (PR) and the neutral red staining (NRS) assays. The PR assay described in this study was modified from the traditional viral plaque reduction assay by using an improved crystal staining method to achieve better plague formation in SCV infected Vero E6 cells. The NRS neutralization assay was adopted from a similar system used for detecting neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1). In this assay, the protective effect of neutralizing antibodies was determined by the cell viability which is measured by the uptake of neutral red dye at A540. The neutralizing antibody titers can be easily determined with either of the two new assays. In this report, we described the utility of these two new neutralization assays in measuring the neutralizing activities against SCV infection from rabbit sera immunized with various forms of spike protein of SCV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15894326</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-1759</ISSN><JournalIssue CitedMedium="Print"><Volume>301</Volume><Issue>1-2</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of immunological methods</Title><ISOAbbreviation>J. Immunol. Methods</ISOAbbreviation></Journal><ArticleTitle>Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).</ArticleTitle><Pagination><MedlinePgn>21-30</MedlinePgn></Pagination><Abstract><AbstractText>Accurate assessment of neutralizing antibody activities is important either for patients infected with Severe Acute Respiratory Syndrome (SARS) or for animals and volunteers immunized with the experimental vaccines against the SARS associated coronavirus (SCV). However, the current assay based on the cytopathic effect (CPE) which has been frequently cited in literature has several limitations. The CPE assay relies on the visual observation on the damage of SCV infected target cells under a microscope. It is subjected to observer variations and it is difficult to generate a quantitative determination of neutralizing activities based on the level of CPE. In the current study, we established the utility of two additional assays to measure the neutralizing activities against SCV: the plaque reduction (PR) and the neutral red staining (NRS) assays. The PR assay described in this study was modified from the traditional viral plaque reduction assay by using an improved crystal staining method to achieve better plague formation in SCV infected Vero E6 cells. The NRS neutralization assay was adopted from a similar system used for detecting neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1). In this assay, the protective effect of neutralizing antibodies was determined by the cell viability which is measured by the uptake of neutral red dye at A540. The neutralizing antibody titers can be easily determined with either of the two new assays. In this report, we described the utility of these two new neutralization assays in measuring the neutralizing activities against SCV infection from rabbit sera immunized with various forms of spike protein of SCV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shixia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakhatskyy</LastName><ForeName>Pavlo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Te-Hui W</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Shan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK032520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 44338</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 40337</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P30DK32520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Immunol Methods</MedlineTA><NlmUniqueID>1305440</NlmUniqueID><ISSNLinking>0022-1759</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15894326</ArticleId><ArticleId IdType="pii">S0022-1759(05)00083-9</ArticleId><ArticleId IdType="doi">10.1016/j.jim.2005.03.008</ArticleId><ArticleId IdType="pmc">PMC7094753</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gesamte Virusforsch. 1971;34(1):40-50</Citation><ArticleIdList><ArticleId IdType="pubmed">5111316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 1988 Jan-Feb;9(1-2):47-55</Citation><ArticleIdList><ArticleId IdType="pubmed">2968777</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Microbiol. 2004 Nov 15;103(3-4):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15504587</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Jan 15;427(6971):185</Citation><ArticleIdList><ArticleId IdType="pubmed">14724600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9294155</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1967 Aug;99(2):291-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4961907</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rev Latinoam Microbiol. 1996 Jul-Dec;38(3-4):167-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10932707</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Health Commun. 2003 Jul-Aug;8(4):297-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12907396</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mayo Clin Proc. 2003 Jul;78(7):882-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12839084</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1906-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15650214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Immunol. 2004 Mar;5(3):233-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Intervirology. 1973;1(4):278-87</Citation><ArticleIdList><ArticleId IdType="pubmed">4359697</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Soc Exp Biol Med. 1968 May;128(1):80-3</Citation><ArticleIdList><ArticleId IdType="pubmed">4968541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Oct;77(19):10684-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12970455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 19;315(4):1134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14985131</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 Jul;73(7):6024-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10364354</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Soc Exp Biol Med. 1967 Jun;125(2):602-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4961492</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1183-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14531382</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 May 28;304(5675):1223-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15166332</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Aug 5;351(6):609-11; author reply 609-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15295057</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 1979 Feb;9(2):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">107192</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 12;362(9378):170</Citation><ArticleIdList><ArticleId IdType="pubmed">12867123</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Mar;72(3):1886-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9499040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1987 May;68 ( Pt 5):1277-88</Citation><ArticleIdList><ArticleId IdType="pubmed">3572365</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Apr 30;304(5671):659-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15118129</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1987 Jan;155(1):146-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3794399</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 May 29;363(9423):1780</Citation><ArticleIdList><ArticleId IdType="pubmed">15174476</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Sep 26;301(5641):1824</Citation><ArticleIdList><ArticleId IdType="pubmed">14512588</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann N Y Acad Sci. 2001 Dec;951:286-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11797785</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Jan 2;303(5654):26</Citation><ArticleIdList><ArticleId IdType="pubmed">14704402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Med. 2003 Sep;115(4):330</Citation><ArticleIdList><ArticleId IdType="pubmed">12967702</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Microbiol (Paris). 1973 Mar;124(2):271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">4127063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 2003 Jul;41(7):3154-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12843056</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002737 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002737 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15894326
|texte= Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15894326" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |